ALX Oncology appoints Dr. Itziar Canamasas to Board of Directors, effective April 11, 2022

ALX ONCOLOGY HOLDINGS INC

Board size increased from six to seven directors; Canamasas appointed as Class II director with term expiring at 2022 Annual Meeting.
Canamasas is Head of Oncology EMEA at Bayer AG with 20+ years of biopharma experience in commercialization and strategy.
Granted initial stock option for 24,009 shares vesting monthly over three years, per director compensation policy.
No arrangements or material transactions between Canamasas and the company other than standard indemnification agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Itziar Canamasas

Director

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2022-04-11
Filed: April 12, 2022, 7:59 PM ET

Effective as of April 11, 2022, the Board of Directors of ALX Oncology Holdings Inc. (the “Company”) appointed Dr. Itziar Canamasas to its Board of Directors and increased the size of its Board of Directors from six to seven directors in connection with her appointment.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Itziar Canamasas was appointed as Director at ALX ONCOLOGY HOLDINGS INC.

Action: appointed
Role: Director

Exact text from the filing

Effective as of April 11, 2022, the Board of Directors of ALX Oncology Holdings Inc. (the “Company”) appointed Dr. Itziar Canamasas to its Board of Directors and increased the size of its Board of Directors from six to seven directors in connection with her appointment.

View on SEC.gov

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0000950170-22-005597

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.